- Kaiser: Insurers deny medical claims more often than you think.
- Enthoven in Health Affairs: likes our new Medicare book. A “must read.”
- Tom Miller: why most health policy is déjà vu.
- Why is mental health declining for young women? (NYT)
- Are Biden’s regulations the reason for a 20% drop in blood tests for transplant patients? (WSJ)
- How can you do a placebo-controlled drug trial if the disease affects only a few dozen people? (WSJ)
Category: Drug Prices & Regulations
The New York Times (and the FDA) Does a Hatchet Job on Regenerative Medicine
The New York Times did a hatchet job on regenerative medicine. A visiting researcher at New York-Presbyterian/Weill Cornell Medical Center and other surgeons had performed numerous surgeries using BioBurst, a processed umbilical cord fluid, to help fuse together bones in minimally invasive surgeries. The fluid was administered to reduce healing time and reduce the need for more invasive back surgery.
Monday Links
- Health gains from key prescription drugs.
- Steve Henke, et. al., skewer a new Royal Society report on Covid-19.
- Health Affairs study: employers lack leverage to negotiate lower prices. Have they never heard of reference pricing?
- CDC: we are losing the battle against obesity. I thought we lost it a long time ago.
- Inequities at the doctors office: is it because the patients don’t speak up for themselves?
Friday Links
- Antibiotic resistance might cause up to 10 million death per year by 2050. (NYT)
- Is global warming causing a spike in poison ivy?
- Survey: 1 in 3 U.S. adults are interested in trying psychedelics like MDMA, known as ecstasy, or psilocybin, the naturally occurring compound in “magic mushrooms,” for their mental health.
- H.R.5608 would allow individuals to elect to receive contributions to a health savings account in lieu of reduced cost-sharing under health insurance obtained through a health insurance Exchange.
- Wisdom > From Larry Summers.
- Alex Tabarrok: drug companies need to make more money, not less.